March 28, 2024

On the Horizon: Asciminib, a New Drug for Treating R/R CML

The investigational drug asciminib (being developed by Novartis) may become the new kid on the block for the treatment of chronic phase chronic myeloid leukemia (CMP-CP) for patients who have relapsed on or are refractory to at least two prior tyrosine kinase inhibitors (TKIs). New results from the ASCEMBL study (NCT03106779) show that patients who…

Source: